{"id":"h1-antihistamines","safety":{"commonSideEffects":[{"rate":"10%","effect":"Drowsiness"},{"rate":"5%","effect":"Dry mouth"},{"rate":"5%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1813863","moleculeType":"Small molecule","molecularWeight":"632.75"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"H1 antihistamines work by competitively inhibiting the action of histamine at H1 receptors, which are found in the brain, blood vessels, and smooth muscle. This leads to a decrease in the symptoms associated with histamine release, such as itching, sneezing, and runny nose.","oneSentence":"Blocks H1 histamine receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:26.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Urticaria"},{"name":"Anaphylaxis"}]},"trialDetails":[{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT07266402","phase":"PHASE3","title":"A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)","status":"RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2026-01-15","conditions":"Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria","enrollment":240},{"nctId":"NCT06445023","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":963},{"nctId":"NCT06455202","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-19","conditions":"Chronic Spontaneous Urticaria","enrollment":976},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT06042478","phase":"PHASE3","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-15","conditions":"Chronic Spontaneous Urticaria","enrollment":470},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT05976243","phase":"PHASE3","title":"A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-07","conditions":"Chronic Inducible Urticaria","enrollment":362},{"nctId":"NCT07109817","phase":"PHASE2","title":"Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03","conditions":"Breast Cancer, Peripheral Neuropathy","enrollment":116},{"nctId":"NCT07415551","phase":"PHASE2","title":"A Multi Dose, Phase 2 Study of YH35324 in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","status":"NOT_YET_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2026-03-31","conditions":"Allergic Diseases, Chronic Spontaneous Urticaria (CSU)","enrollment":150},{"nctId":"NCT07358780","phase":"","title":"Remibrutinib in Real-world Clinical Practice - a US Sub-study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-02","conditions":"Chronic Spontaneous Urticaria","enrollment":505},{"nctId":"NCT07402213","phase":"PHASE3","title":"Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-03-31","conditions":"Chronic Spontaneous Urticaria","enrollment":180},{"nctId":"NCT07358364","phase":"","title":"Remibrutinib in Real-world Clinical Practice","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-02","conditions":"Chronic Spontaneous Urticaria","enrollment":3280},{"nctId":"NCT06053801","phase":"","title":"A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-16","conditions":"Chronic Spontaneous Urticaria","enrollment":55},{"nctId":"NCT07378527","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria","status":"NOT_YET_RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2026-03","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":344},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT06162728","phase":"PHASE1, PHASE2","title":"Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jasper Therapeutics, Inc.","startDate":"2023-11-29","conditions":"Chronic Spontaneous Urticaria","enrollment":88},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT07062627","phase":"PHASE2","title":"Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma","status":"RECRUITING","sponsor":"Hyungwoo Cho","startDate":"2025-11-12","conditions":"Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":12},{"nctId":"NCT06228560","phase":"PHASE2","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Longbio Pharma","startDate":"2024-01-26","conditions":"Chronic Spontaneous Urticaria","enrollment":202},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05795153","phase":"PHASE3","title":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-04-05","conditions":"Chronic Spontaneous Urticaria","enrollment":144},{"nctId":"NCT06353971","phase":"PHASE1, PHASE2","title":"A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines","status":"TERMINATED","sponsor":"Jasper Therapeutics, Inc.","startDate":"2024-03-18","conditions":"Chronic Inducible Urticaria","enrollment":27},{"nctId":"NCT04976192","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2021-08-30","conditions":"Chronic Urticaria","enrollment":608},{"nctId":"NCT06801626","phase":"PHASE3","title":"Novel Strategies for Reducing Burn Scar Itch","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2025-03-01","conditions":"Burn Scar, Itch Scarring, Wound","enrollment":44},{"nctId":"NCT04681729","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-10","conditions":"Cold Urticaria","enrollment":82},{"nctId":"NCT06577116","phase":"PHASE1","title":"Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2024-08-28","conditions":"Chronic Spontaneous Urticaria","enrollment":29},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT04426890","phase":"PHASE3","title":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-12-09","conditions":"Chronic Spontaneous Urticaria","enrollment":634},{"nctId":"NCT05677451","phase":"PHASE3","title":"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":100},{"nctId":"NCT06072157","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2023-08-28","conditions":"Healthy Participants, Chronic Spontaneous Urticaria","enrollment":136},{"nctId":"NCT05032157","phase":"PHASE3","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-01","conditions":"Chronic Spontaneous Urticaria","enrollment":455},{"nctId":"NCT05048342","phase":"PHASE3","title":"A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-15","conditions":"Chronic Spontaneous Urticaria","enrollment":71},{"nctId":"NCT05030311","phase":"PHASE3","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Chronic Spontaneous Urticaria","enrollment":470},{"nctId":"NCT03907878","phase":"PHASE3","title":"A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-13","conditions":"Chronic Spontaneous Urticaria","enrollment":66},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":"Post COVID-19 Condition, Long COVID Syndrome, Persistent COVID-19","enrollment":90},{"nctId":"NCT05774639","phase":"PHASE3","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2023-08-15","conditions":"Chronic Idiopathic Urticaria","enrollment":600},{"nctId":"NCT03719924","phase":"PHASE2","title":"Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2019-03-07","conditions":"Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT06396026","phase":"PHASE3","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2024-12-24","conditions":"Chronic Spontaneous Urticaria","enrollment":436},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT05528861","phase":"PHASE2","title":"A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria","status":"TERMINATED","sponsor":"Allakos Inc.","startDate":"2022-10-26","conditions":"Chronic Spontaneous Urticaria","enrollment":127},{"nctId":"NCT06118710","phase":"PHASE4","title":"Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-25","conditions":"Cancer","enrollment":500},{"nctId":"NCT05335499","phase":"PHASE2","title":"A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2022-06-28","conditions":"Chronic Spontaneous Urticaria","enrollment":126},{"nctId":"NCT06519344","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","startDate":"2024-07-31","conditions":"B Cell Malignancies","enrollment":12},{"nctId":"NCT05107115","phase":"PHASE2","title":"Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-11-24","conditions":"Chronic Spontaneous Urticaria","enrollment":161},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-01-03","conditions":"Poisoning","enrollment":24},{"nctId":"NCT01918033","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-08-20","conditions":"Perennial Allergic Rhinitis","enrollment":608},{"nctId":"NCT05024058","phase":"PHASE3","title":"Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-16","conditions":"Chronic Inducible Urticaria","enrollment":39},{"nctId":"NCT01916967","phase":"PHASE3","title":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-08-27","conditions":"Urticaria","enrollment":239},{"nctId":"NCT06375161","phase":"EARLY_PHASE1","title":"Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.","status":"RECRUITING","sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","startDate":"2023-12-11","conditions":"B Cell Malignancies","enrollment":12},{"nctId":"NCT04990388","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-10-18","conditions":"Glycogen Storage Disease Type III","enrollment":9},{"nctId":"NCT06217367","phase":"PHASE4","title":"Over-the-Counter Antihistamines & Heat Stress","status":"UNKNOWN","sponsor":"Lakehead University","startDate":"2023-12-05","conditions":"Heat Illness, Allergic Rhinitis, Heat Injury","enrollment":16},{"nctId":"NCT05451784","phase":"PHASE1, PHASE2","title":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2022-07-20","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT03749148","phase":"PHASE2","title":"Cholinergic Urticaria - Efficacy of Dupilumab","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-12-10","conditions":"Cholinergic Urticaria","enrollment":48},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT03926611","phase":"PHASE2","title":"This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-06","conditions":"Chronic Spontaneous Urticaria","enrollment":311},{"nctId":"NCT05276336","phase":"PHASE3","title":"The Effect of Early Radiofrequency Turbinate Reduction on Persistent Allergic Rhinitis","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2018-07-01","conditions":"Allergic Rhinitis","enrollment":32},{"nctId":"NCT04159701","phase":"PHASE2","title":"A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-11-15","conditions":"Chronic Spontaneous Urticaria","enrollment":52},{"nctId":"NCT01601522","phase":"PHASE2","title":"Peanut Allergy Oral Immunotherapy Desensitization","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2012-02","conditions":"Peanut Allergy","enrollment":43},{"nctId":"NCT03749135","phase":"PHASE2","title":"Dupilumab in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-12","conditions":"Chronic Spontaneous Urticaria, Recurrent Angioedema","enrollment":72},{"nctId":"NCT04004637","phase":"PHASE1","title":"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2019-08-25","conditions":"T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia","enrollment":10},{"nctId":"NCT01723072","phase":"PHASE3","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-23","conditions":"Chronic Spontaneous Urticaria, Angioedema","enrollment":91},{"nctId":"NCT02906670","phase":"PHASE1, PHASE2","title":"Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies","status":"TERMINATED","sponsor":"Symphogen A/S","startDate":"2016-11-01","conditions":"Oncology","enrollment":32},{"nctId":"NCT04399525","phase":"NA","title":"Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-10-28","conditions":"Pruritus","enrollment":12},{"nctId":"NCT04399148","phase":"NA","title":"Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-06-11","conditions":"Pruritus","enrollment":13},{"nctId":"NCT02550106","phase":"PHASE4","title":"Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-22","conditions":"CHRONIC SPONTANEOUS URTICARIA","enrollment":136},{"nctId":"NCT02984397","phase":"PHASE3","title":"Chronic Widespread Pain and White Blood Cell Activation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-12","conditions":"Widespread Chronic Pain","enrollment":44},{"nctId":"NCT03296358","phase":"NA","title":"Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-10-01","conditions":"Urticaria, Allergy","enrollment":75},{"nctId":"NCT04237428","phase":"NA","title":"CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2019-05-31","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":"Indolent Systemic Mastocytosis","enrollment":135},{"nctId":"NCT01443442","phase":"PHASE4","title":"Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2011-10","conditions":"Allergic Conjunctivitis","enrollment":23},{"nctId":"NCT03183024","phase":"PHASE4","title":"Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody","status":"COMPLETED","sponsor":"Jonathan A. Bernstein, MD","startDate":"2017-09-12","conditions":"Chronic Idiopathic Urticaria","enrollment":12},{"nctId":"NCT02814630","phase":"NA","title":"Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Asthma Inc Clinical Research Center","startDate":"2016-09","conditions":"Chronic Idiopathic Urticaria","enrollment":20},{"nctId":"NCT02626221","phase":"","title":"A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-24","conditions":"Chronic Urticaria","enrollment":497},{"nctId":"NCT02372604","phase":"PHASE3","title":"Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-07","conditions":"Chronic Spontaneous Urticaria","enrollment":15},{"nctId":"NCT01569191","phase":"PHASE4","title":"Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aston University","startDate":"2012-03","conditions":"Hypersensitivity","enrollment":18},{"nctId":"NCT00605852","phase":"PHASE1","title":"Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-29","conditions":"Rhinitis, Allergic, Seasonal","enrollment":29},{"nctId":"NCT02031679","phase":"PHASE2","title":"Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-01","conditions":"Chronic Idiopathic Urticaria","enrollment":38},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT02329223","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12","conditions":"Chronic Spontaneous Uriticaria","enrollment":218},{"nctId":"NCT02653339","phase":"NA","title":"Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-06","conditions":"Rhinitis, Allergic, Perennial","enrollment":180},{"nctId":"NCT02507635","phase":"PHASE4","title":"Anti-inflammatory H1 Antihistamines Allergic Rhinitis","status":"COMPLETED","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2009-02","conditions":"Allergic Rhinitis","enrollment":115},{"nctId":"NCT01599637","phase":"PHASE2","title":"Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Idiopathic Urticaria","enrollment":40},{"nctId":"NCT01287117","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":319},{"nctId":"NCT01264939","phase":"PHASE3","title":"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":336},{"nctId":"NCT01292473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-03","conditions":"Chronic Idiopathic Urticaria","enrollment":323},{"nctId":"NCT00000363","phase":"PHASE3","title":"Acute Otitis Media: Adjuvant Therapy to Improve Outcome","status":"COMPLETED","sponsor":"National Institute on Deafness and Other Communication Disorders (NIDCD)","startDate":"","conditions":"Otitis Media","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":766,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"H1 antihistamines","genericName":"H1 antihistamines","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks H1 histamine receptors Used for Allergic rhinitis, Urticaria, Anaphylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}